Q4 2020 13F Holders as of 12/31/2020
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
93.1M
-
Number of holders
-
174
-
Total 13F shares, excl. options
-
74.8M
-
Shares change
-
+1.7M
-
Total reported value, excl. options
-
$1.48B
-
Value change
-
+$41M
-
Put/Call ratio
-
0.83
-
Number of buys
-
70
-
Number of sells
-
-87
-
Price
-
$19.78
Significant Holders of MYRIAD GENETICS INC - Common Stock, par value $0.01 per share (MYGN) as of Q4 2020
210 filings reported holding MYGN - MYRIAD GENETICS INC - Common Stock, par value $0.01 per share as of Q4 2020.
MYRIAD GENETICS INC - Common Stock, par value $0.01 per share (MYGN) has 174 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 74.8M shares
of 93.1M outstanding shares and own 80.33% of the company stock.
Largest 10 shareholders include BlackRock Inc. (12.5M shares), VANGUARD GROUP INC (8.3M shares), EARNEST PARTNERS LLC (6.73M shares), Camber Capital Management LP (5M shares), STATE STREET CORP (3.72M shares), GLENVIEW CAPITAL MANAGEMENT, LLC (3.68M shares), D. E. Shaw & Co., Inc. (3.22M shares), DIMENSIONAL FUND ADVISORS LP (2.76M shares), BANK OF AMERICA CORP /DE/ (2.6M shares), and MORGAN STANLEY (2.22M shares).
This table shows the top 174 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.